<DOC>
	<DOCNO>NCT00826150</DOCNO>
	<brief_summary>This study design assess safety , tolerability , pharmacokinetics ( PK ) preliminary efficacy DTA-H19 administer intraperitoneally ( IP ) subject advanced stage ovarian cancer , primary peritoneal carcinoma</brief_summary>
	<brief_title>Phase 1/2a Study DTA-H19 Advanced Stage Ovarian Cancer</brief_title>
	<detailed_description>This Phase 1/2a , open label , dose escalation , repeat dose study 11 subject recurrent , platinum resistant advance stage ovarian cancer primary peritoneal carcinoma design determine tolerability , safety , quality life , PK , preliminary efficacy DTA-H19 administer intraperitoneally ( IP ) . Primary Objective : The primary objective study : - To determine maximum tolerate dose ( MTD ) IP DTA-H19 ; , - To identify dose limit toxicity ( DLTs ) . Secondary Objectives : Secondary objective study : - To determine quality life subject advanced ovarian cancer , primary peritoneal carcinoma treat IP DTA-H19 ; - To determine reduction malignant ascites measure Ultrasound change frequency parecenteses necessary . - To determine overall survival distribution .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>Provide write informed consent least 18 year age . Have histopathologically document epithelial ovarian carcinoma primary peritoneal carcinoma evidence ascites . Have either ) platinumrefractory disease ( i.e . persistent disease follow completion platinumbased primary chemotherapy ) fail least primary platinumbased chemotherapy ; b ) platinumresistant recurrent disease fail least one regimen second line chemotherapy . Be able tolerate placement IP catheter . Be least 2 week last treatment allow recovery prior toxicity judgment investigator sufficient time ensure effect prior treatment confound safety evaluation . Have Karnofsky performance status score ≥ 70 % . Not childbearing potential . Have life expectancy ≥ 3 month . Have serum creatinine &lt; 2.0 mg/dL , total bilirubin less institution 's 3x upper limit normal ( ULN ) ; AST ALT &lt; = 2.5 x ULN , total albumin ≥ 2.5 g/dL , PT , PTT , PT/INR within normal limit , absolute neutrophil count ( ANC ) &gt; 1,500 x 103 cells/mL , platelet ≥ 100,000/mL , hemoglobin ≥ 10 mg/dL . Have biopsy specimen ascites fluid positive H19 expression . Have screen procedure complete within 6weeks start treatment . No significant history cardiac disease , i.e. , uncontrolled hypertension , unstable angina congestive heart failure . No plan receive concurrent chemotherapy , hormonal therapy , radiotherapy , immunotherapy type therapy treatment cancer protocol . Have evidence extra abdominal disease exception isolate small nodule ( e.g. , liver pulmonary nodule ) cause symptom . Have know brain metastasis . Have know HIV infection . Have know active viral bacterial infection . Have presence psychological , familiar , sociological , geographical condition potentially hamper compliance study protocol follow schedule . Have medical condition contraindicate laparotomy , laparoscopy , surgery . Have significant bowel involvement denote persistent grade 3 vomiting ( ≥6 episodes 24 hr ; IV fluid , total parenteral nutrition ( TPN ) indicate ≥24 hr ) removal ascites , inability tolerate oral diet medication , requirement total parenteral nutrition , recent ( past six week ) episode bowel obstruction . Have history coagulopathy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>H19 gene</keyword>
	<keyword>plasmid</keyword>
</DOC>